Hojatizade Mansure, Soleymani Mahsa, Tafaghodi Mohsen, Badiee Ali, Chavoshian Omid, Jaafari Mahmoud Reza
Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Iran J Immunol. 2018 Dec;15(4):281-293. doi: 10.22034/IJI.2018.39397.
Although there have been numerous attempts to develop vaccines for Leishmaniasis, no vaccine can be found against Leishmania in routine use for an effective global vaccination. It seems that one of the reasons for the low efficacy of such vaccines is the lack of a suitable adjuvant.
To evaluate the effects of chitosan nanoparticles containing whole Leishmania lysate antigen (WLL) and soluble leishmania antigens (SLA), a first generation Leishmania vaccine, on the type of immune response generated in BALB/c in a murine model of leishmaniasis.
The optimum coating ratio between the polymer and antigens was determined according to their physico-chemical properties such as particle size and zeta potential. Chitosan nanoparticles were loaded with antigens via ionic gelation method. BALB/c mice were immunized subcutaneously three times with various nanoparticulate and free antigens with 2-week intervals.
There was no significant (P > 0.05) difference concerning the footpad thickness of mice immunized with nanoparticulate formulations containing either SLA or WLL during the experiment period; these formulations induced a strong mixed Th1/Th2 type immune response characterized by the production of IFN-γ and IL-4, and high levels of IgG2a IgG1 anti-Leishmania antibody.
Nanoparticulate formulations (CHT: SLA and CHT: WLL) are not suitable candidates for preferential induction of a pure Th1-type immune response and immunization against Leishmania infection. However, it might be a good strategy in other infectious diseases where a mixed Th1/Th2 immune response is required.
尽管已经进行了许多开发利什曼病疫苗的尝试,但在常规全球疫苗接种中尚未发现针对利什曼原虫的有效疫苗。此类疫苗效力低下的原因之一似乎是缺乏合适的佐剂。
在利什曼病小鼠模型中,评估含全利什曼原虫裂解物抗原(WLL)和可溶性利什曼原虫抗原(SLA)的壳聚糖纳米颗粒(第一代利什曼原虫疫苗)对BALB/c小鼠产生的免疫反应类型的影响。
根据聚合物和抗原的物理化学性质(如粒径和zeta电位)确定聚合物与抗原之间的最佳包被比例。通过离子凝胶法将壳聚糖纳米颗粒负载抗原。BALB/c小鼠皮下免疫3次,分别接种各种纳米颗粒抗原和游离抗原,间隔2周。
在实验期间,用含SLA或WLL的纳米颗粒制剂免疫的小鼠足垫厚度无显著差异(P>0.05);这些制剂诱导了强烈的Th1/Th2混合型免疫反应,其特征是产生IFN-γ和IL-4,以及高水平的抗利什曼原虫IgG2a和IgG1抗体。
纳米颗粒制剂(CHT:SLA和CHT:WLL)不是优先诱导纯Th1型免疫反应和预防利什曼原虫感染免疫接种的合适候选物。然而,在需要Th1/Th2混合型免疫反应的其他传染病中,这可能是一种很好的策略。